Neihulizumab
Neihulizumab (ALTB-168) is an immune checkpoint agonistic antibody that binds to human CD162 (PSGL-1), leading to downregulation of activated T-cells. Neihulizumab can be uesd for steroid-refractory acute graft-versus-host-disease (SR-aGVHD), psoriasis, psoriatic arthritis and ulcerative colitis research[1].
Product Specifications
CAS Number
[2158362-38-8]
Product Name Alternative
ALTB-168; Anti-PSGL1/CD162 Reference Antibody (neihulizumab)
UNSPSC
12352203
Target
Apoptosis
Type
Inhibitory Antibodies
Related Pathways
Apoptosis
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/neihulizumab.html
Purity
99.0
Solubility
10 mM in DMSO
Smiles
[Neihulizumab]
Molecular Weight
(145.72 kDa)
References & Citations
[1]Sameem Abedin, et al. Experimental Pharmaceuticals for Steroid-Refractory Acute Graft-versus-Host Disease. J Exp Pharmacol. 2020 Nov 26;12:549-557.|[2]Sameem Abedin, et al. Neihulizumab (ALTB-168) in Patients with Steroid-Refractory Acute Graft-Versus-Host-Disease (SR-aGVHD) or Treatment-Refractory Acute Graft-Versus-Host-Disease (TR-aGVHD) . Blood (2022) 140 (Supplement 1) : 10495-10497.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
